Tacrolimus capsule (low-dose) ( DrugBank: Tacrolimus )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 227 | Osler disease | 1 |
227. Osler disease
Clinical trials : 54 / Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04646356 (ClinicalTrials.gov) | October 20, 2020 | 20/10/2020 | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Hereditary Hemorrhagic Telangiectasia;Epistaxis Nosebleed | Drug: Tacrolimus capsule (low-dose) | Unity Health Toronto | United States Department of Defense | Recruiting | 18 Years | N/A | All | 30 | Phase 2 | Canada |